AEGiS-07IAC: HIV-GP160 recombinant vaccinia vaccination of vaccinia-naive adults followed by RGP160 booster immunization.

7th International AIDS Conference


Florence, Italy — June 16-21, 1991

Print this Article


HIV-GP160 recombinant vaccinia vaccination of vaccinia-naive adults followed by RGP160 booster immunization.

Int Conf AIDS 1991 Jun 16-21; 7:88 (abstract no. F.A.1)
Graham BS, Belshe R, Clements ML, Dolin R, Fernie B, Stablein D, Wright P, Koff W; Bethesda, MD

OBJECTIVE: To assess the safety and immunogenicity of recombinant vaccinia encoding the gp160 of HIV-1LAV-1 (HIVAC-le, Oncogen/Bristol-Myers Squibb) in vaccinia-naive adults.

METHODS: HIVAC-le was compared to its parent vaccinia strain (Dryvax, Wyeth) in 36 healthy, vaccinia-naive adults in a randomized, double-blind study. HIVAC-1e (10(7) or 10(8)/ml) or Dryvax was administered using bifurcated needle punctures. HIVAC-le recipients are currently being boosted with 640 mug rgp160 (VaxSyn, MicroGeneSys).

RESULTS: Vaccination with 10(7) or 10(8) resulted in primary takes for all Dryvax and HIVAC-le recipients that were vaccinia-seronegative. Neither local/systemic reactions nor virus titer in lesions differed significantly between vaccines or between doses. In HIVAC-le recipients with takes antibody (Ab) to gp160 was detected by western blot assay in 8/10 at 10(7) and 7/10 at 10(8) and persisted greater than 365 days in 7/11 responders. gp160-specific lymphoproliferation (LP) was also detected in HIVAC-le recipients and persisted greater than 365 days. Boosting HIVAC-le recipients with rgp160 has caused no adverse local or systemic reactions to date. HIV-1 neutralizing Ab assays and additional LP assays are in progress.

CONCLUSIONS: We report the first trial utilizing live recombinant vaccinia virus to immunize vaccinia-naive individuals. Expression of gp160 did not alter the virulence of the vaccinia vector. HIVAC-le induced Ab to gp160 more frequently in vaccinia-naive persons than has been reported for vaccinia-seropositive persons. HIV-1 specific Ab and LP responses appear to be more persistent in HIVAC-le immunized persons than in persons immunized with rgp160 alone. HIVAC-le has potential as a primary vaccine product, and may have unique qualities for priming the immune response for subunit boosting.

Keywords: AEGIS, AIDS Vaccines, Immunization, Secondary, Vaccination, HIV Antibodies, HIV-1, Vaccinia virus, Blotting, Western, HIVAC-1e, VaxSyn HIV-1 (gp160) vaccine, Adult, ICA7KWDaegis,aidsvaccines,immunization,secondary,vaccination,hivantibodies,hiv-1,vacciniavirus,blotting,western,hivac-1e,vaxsynhiv-1(gp160)vaccine,adult,ica7
910616
FA1

Copyright © 1991 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.